Fiasp FlexTouch 300IU Pen – Ultra Rapid-Acting Insulin for Mealtime Blood Sugar Control
Fiasp FlexTouch 300IU Pen contains insulin aspart in a fast-acting formulation designed to help manage blood glucose levels around meals in individuals with diabetes mellitus under medical supervision. It is a rapid-acting insulin used to control post-meal blood sugar spikes and is typically prescribed as part of a broader insulin therapy plan.
Fiasp (faster insulin aspart) is formulated to begin working more quickly than standard insulin aspart, helping to improve glucose control shortly after eating. It is commonly used in patients with type 1 diabetes and type 2 diabetes who require mealtime insulin in addition to basal insulin therapy.
Each FlexTouch pen contains a total of 300 international units (IU) of insulin and is designed for convenient, pre-set dosing. The pen device allows for precise and easy administration, supporting better adherence to treatment schedules and improved daily management of blood glucose levels.
Because insulin therapy is highly individualized, dosing and timing must always be determined by a qualified healthcare professional. Factors such as diet, activity level, current glucose readings, and overall treatment plan all influence insulin requirements.
Patients using Fiasp are typically advised to monitor their blood glucose regularly to reduce the risk of hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar). Proper injection technique and site rotation are also important to ensure consistent absorption and effectiveness.
Fiasp FlexTouch should be stored according to manufacturer guidelines, typically in a refrigerator before first use and at controlled room temperature after opening for a limited time. It should be kept away from heat and direct light.
As a modern mealtime insulin option, Fiasp FlexTouch 300IU Pen is widely used in clinical diabetes management to provide flexible and rapid blood sugar control when used under medical supervision.
